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Oral mucositis (OM) is a clinically significant problem affecting 
more than 90% of patients with cancers of the head and neck 
area, undergoing radiotherapy where the oral cavity is located 
within the clinical target volume (CTV). The clinical effect of OM 
is the result of the existence of the following factors: 
• generating symptoms (pain, taste disorders, difficulties in 
swallowing), leading to disorders of the water and elec-
trolyte metabolism and, finally, malnutrition,
• significant deterioration in quality of life, and 
• limitation of radiotherapy tolerance which might lessen 
treatment effects  [1–3].
The patomechanism of the development of radiotherapy-
-induced OM is well studied and described. This is a multi-stage 
process, comprising: 
• damage (as a result of the ionising irradiation) and the 
death of cells within the basal layer and generation of 
free radicals, 
• development of an inflammatory reaction which stimu-
lates the cells’ death,
• the production of proinflammatory cytokines stimulating the 
development of  ulceration, leading to secondary infection,
• final stage (healing), with the proliferation and differentia-
tion of epithelial cells [4, 5]. 
This process was described in detail in the paper:  Oral 
mucositis (OM) – a common problem of oncologists and dentists. 
There are also many factors affecting the risk of OM de-
velopment during radiotherapy [1, 3, 6–12] – three groups of 
factors can be distinguished here:  
1. Treatment induced, comprising: the size of the radio-
therapy dose and the fractionating pattern, as well as the 
use of chemotherapy; these factors not only affect the 
intensification of OM, but also the moment of its develop-
ment (positive correlation between the dose and intensity 
of OM; in the case of the administration of accelerated 
fractionation (AF) of a dose, the symptoms of OM develop 
earlier and they are more intensive, whilst the application 
of combined treatment – chemo-radiotherapy, especially 
with weekly administration of cisplatin – leads to an effect 
Table I. The comparison of the scales RTOG/EORTC and CTCAE, to complete the publication in which the WHO scale was discussed by the authors of the 
paper Oral Mucositis (OM) – a Common Problem for Oncologists and Dentists 
Intensity RTOG/EORTC [13] CTCAE [14]
G1 low intensity of erythema and pain (does not require 
treatment) 
no symptoms or mild symptoms
G2 focal serous mucositis, moderate pain (require the use of 
analgesic agents)
moderate pain, retained ability of oral food intake, necessity to 
modify diet 
G3 diffuse inflammation with fibrin production, significant pain 
(require the administration of narcotic analgesics)
severe pain, impaired food intake 
G4 ulceration, bleeding, necrosis life threatening condition, requiring urgent intervention  
G5 death 
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which is cumulative  with regards both to the intensity 
and duration of  OM); 
2. Cancer-induced, which comprise, first of all, the location 
and size of the primary tumour, determining the clinical 
target volume and the size of the irradiated mucosal mem-
brane of the oral cavity and salivary glands; 
3. Characteristic of the patient, which do not only deter-
mine the risk of development, but also the intensity and 
duration of  OM. These comprise:  patient age, a history of 
tobacco and alcohol consumption, the presence of metal 
dentures, co-existing periodontal conditions, low body 
mass index (BMI), limited degree of physical fitness, de-
creased leucocyte count, advanced cancer stage, a history 
of oral cavity diseases, comorbidities and gene polymor-
phism (XRCC1, NBN), determining the cytokine phenotype 
facilitating the development of OM.
There are various scales used in clinical practice for the 
evaluation of the intensity of lesions within the oral mucosa 
(RTOG/EOTC, WHO, CTCAE) [1, 13, 14] (tab I). 
OM is a problem which decreases the efficacy of radio-
therapy (as it involves the necessity of intervals in therapy), 
deteriorates the patients’ quality of life (OM symptoms and 
clinical outcomes), therefore the selection of effective treat-
ment methods is necessary. Correct prophylaxis and treatment 
(i.e. symptomatic interventions and targeted methods) reduce 
OM intensity and thus will allow for the improvement of the 
efficacy of the local treatment and of patient survival. The 
significance of this grave clinical problem, as the development 
OM definitely is, justifies thoroughly working out the guidelines 
concerning its prophylaxis and treatment. 
In 2019 an attempt was made to update the guidelines 
of MASCC/ISOO on the basis of the existing publications [16]. 
The results of this update and the recommendations of the 
Polish Group of Specialists in Prophylaxis and Treatment of 
Complications within the Oral Cavity published in 2015, and 
comprising the prophylaxis and treatment to be applied in 
patients undergoing radiotherapy, were discussed in detail in 
the paper: Oral Mucositis (OM) – a Common Problem of Onco-
logists and Dentists.  
The MASCC/ISOO guidelines (update from 2019) confirm 
the significance of basic rules of oral hygiene in OM prophylaxis 
and the benefits resulting from adequate patient education [16]. 
The clinical significance of OM as well as the data coming 
from current publications point to the importance of oral 
hygiene in OM prophylaxis and treatment, and delineate the 
role of dentists in multi-disciplinary therapeutic proceedings 
in patients with head and neck cancers. The role of the dentist 
in OM prophylaxis and treatment cannot be overestimated. 
The algorithm of dental care of oncological patients, worked 
out in 2009 [17], confirms the necessity of interdisciplinary 
collaboration between oncologists and dentists. 
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